Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to -$6.5 million.

  • Theravance Biopharma's Free Cash Flow fell 2488.97% to -$6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $243.5 million, marking a year-over-year increase of 207881.52%. This contributed to the annual value of -$11.9 million for FY2024, which is 5975.24% up from last year.
  • According to the latest figures from Q3 2025, Theravance Biopharma's Free Cash Flow is -$6.5 million, which was down 2488.97% from $208.1 million recorded in Q2 2025.
  • Over the past 5 years, Theravance Biopharma's Free Cash Flow peaked at $208.1 million during Q2 2025, and registered a low of -$124.3 million during Q4 2022.
  • Over the past 5 years, Theravance Biopharma's median Free Cash Flow value was -$12.2 million (recorded in 2023), while the average stood at -$11.8 million.
  • Per our database at Business Quant, Theravance Biopharma's Free Cash Flow tumbled by 17207.29% in 2022 and then skyrocketed by 477476.97% in 2025.
  • Over the past 5 years, Theravance Biopharma's Free Cash Flow (Quarter) stood at -$45.7 million in 2021, then crashed by 172.07% to -$124.3 million in 2022, then skyrocketed by 98.77% to -$1.5 million in 2023, then rose by 28.67% to -$1.1 million in 2024, then plummeted by 495.97% to -$6.5 million in 2025.
  • Its Free Cash Flow was -$6.5 million in Q3 2025, compared to $208.1 million in Q2 2025 and $43.0 million in Q1 2025.